We’re excited to participate in BIO Japan 2024 and showcase our latest advancements in biopharmaceuticals. Visit the partnering zone (Room # PRT-5) to discuss how our innovative solutions can support your manufacturing objective. Arrange a meeting in advance: https://lnkd.in/g5FwenV #SamsungBiologics #CDMO #pharma #biotech #networking #partnership
삼성바이오로직스
제약
Incheon Yeonsu-gu 팔로워 46,033명
Innovation, passion and an unwavering dedication to find breakthrough solutions in biomedicines.
소개
Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.
- 웹사이트
-
https://www.samsungbiologics.com
삼성바이오로직스 외부 링크
- 업계
- 제약
- 회사 규모
- 직원 1,001 - 5,000명
- 본사
- Incheon Yeonsu-gu
- 유형
- 상장기업
- 설립
- 2011
위치
삼성바이오로직스 직원
업데이트
-
Learn more about our biomanufacturing capabilities and new tech platforms designed to accelerate development timelines and enhance quality. Kevin Sharp, Senior Vice President and Head of Global Sales, shares his insights on industry trends and our latest business developments in this BPI Theater interview. Watch now: https://lnkd.in/grQHTCF9 #BIO2024 #SamsungBiologics #CDMO #CDO #Biopharma
-
In today’s rapidly evolving drug development landscape, partnership between innovative biopharmaceutical companies and resource-rich CDMOs is vital for ensuring global access to essential medicines. In these roundtable discussions, our project managers, Jaewon Mun and Justin Kong, offer their insights on: How advanced technologies and customizable models enable CDMOs to provide enhanced support throughout the drug development life cycle, ultimately driving client success: https://lnkd.in/gAVhx_uR How such strategic partnerships are accelerating the delivery of life-saving treatments to patients worldwide: https://lnkd.in/gMnsAZ4i #SamsungBiologics #CDMO #DrugDevelopment #Biopharmaceutical #Partnership
-
Join us at Bioprocess International 2024 in Boston next month! Our CDO experts will showcase S-CHOice®, our proprietary cell line platform designed for scalable manufacturing, during a speaking session on September 24 at 1:00 PM (ET). Visit us at Booth #1025 throughout the event to discuss your project needs. We look forward to connecting with you! https://lnkd.in/gA2tCrMq #SamsungBiologics #BPI #partnership #networking
-
Antibody-drug conjugates (ADCs) are a promising cancer therapy, delivering potent drugs directly to tumor cells. In this article, Yoonjin Kwon, a Lead Scientist in ADC Analytical Method Development, shares her insights on the challenges and emerging trends in ADC development, drawing from her extensive experience. Read more: https://lnkd.in/gGXMJri6 #SamsungBiologics #ADCs #analytical #innovation
-
Intensified Fed-Batch (IFB) culture represents a significant advancement in biopharmaceutical manufacturing, addressing the limitations of traditional fed-batch (TFB) processes. This whitepaper discusses how our advanced IFB platform, S-Tensify™, enables faster and efficient development cycles while maintaining high quality across various therapeutic modalities. https://lnkd.in/gwUhnhGp #SamsungBiologics #IFB #n-1perfusion #cdo #S-Tensify
-
We’re delighted to be part of CPHI Worldwide 2024 in Milan. Mark your calendars and join us at Booth #5B33 from October 8-10. We look forward to connecting with you there and sharing all the capabilities and services we have to offer. https://lnkd.in/g5FwenV #SamsungBiologics #networking #CPHI
이 콘텐츠는 여기에서 사용할 수 없습니다.
LinkedIn 앱에서 이 콘텐츠 등 이용하기
-
During drug development, it is crucial to identify protein sequence variants (SV) – unintended variations resulting from DNA mutations or other genetic changes – as they can impact the safety and efficacy of drugs. In this whitepaper, we explain how Samsung Biologics tackles such challenges with its innovative methods, ensuring high-quality production. https://lnkd.in/eNJZ3w8s #SamsungBiologics #SVs #DrugDevelopment #CLD
-
Building a robust digital infrastructure is crucial for enhancing client satisfaction in drug development and manufacturing. With our commitment to client satisfaction, we streamline processes and swiftly adapt to market demands, helping our clients deliver life-saving biomedicines to patients worldwide. Read more: https://lnkd.in/gk2VK9i2 #SamsungBiologics #digitalization #innovation
-
How can tech transfers and scale-up processes be executed seamlessly, enabling on-time delivery in a shifting regulatory landscape? Leveraging our robust MSAT expertise and advanced technologies, we ensure the success and quality of final products to reach patients in need: https://lnkd.in/gDameW2X #SamsungBiologics #TechTransfer #MSAT